| 1 |
NCT03811275 |
Recruiting |
Task or Virtual Reality Intervention for Improving UE Function |
- Upper Extremity Paresis
- Hemiplegia and/or Hemiparesis Following Stroke
- Hemiplegic Cerebral Palsy
|
- Behavioral: Virtual Reality (A) then Task (B)
- Behavioral: Task (B) then Virtual Reality (A)
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Change in Fugl-Meyer Assessment (UE portion)
- Change in Box & Block Test
- Change in Stroke Impact Scale 3.0
- (and 2 more...)
|
15 |
All |
18 Years to 89 Years (Adult, Older Adult) |
NCT03811275 |
IdahoSU |
|
September 8, 2018 |
August 1, 2020 |
August 1, 2020 |
January 21, 2019 |
January 21, 2019 |
|
- Nancy L Devine
Pocatello, Idaho, United States
|
|
| 2 |
NCT03793686 |
Recruiting |
A Study of Safety of PBCLN-003 Following Antibiotic Therapy in Subjects With C.Difficile-associated Diarrhea |
- Clostridium Difficile Diarrhea
|
- Drug: PBCLN-003
- Drug: Placebo
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Characterization of Adverse Events in a dose escalation study of PBCLN-003
|
48 |
All |
18 Years and older (Adult, Older Adult) |
NCT03793686 |
18-CT-001 |
|
December 6, 2018 |
October 2019 |
November 2019 |
January 4, 2019 |
April 4, 2019 |
|
- Infectious Disease Specialist
Idaho Falls, Idaho, United States
|
|
| 3 |
NCT03736395 |
Recruiting |
Scaling up Schoolwide Positive Behavioral Interventions and Supports (SWPBIS) in Rural Idaho Schools |
|
- Behavioral: Idaho Rural Implementation Model
- Behavioral: Control
|
Interventional
|
Not Applicable |
- Boise State University
- U.S. Department of Justice
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change over time in student disciplinary outcomes
- Change in student academic outcomes
- Fidelity of school implementation of positive behavioral interventions and supports (PBIS)
- Student perceptions of school climate
|
14000 |
All |
5 Years and older (Child, Adult, Older Adult) |
NCT03736395 |
2017-CK-BX-0021 |
I-RIM |
January 1, 2019 |
June 30, 2021 |
December 31, 2021 |
November 9, 2018 |
July 10, 2019 |
|
- Boise State University
Boise, Idaho, United States
|
|
| 4 |
NCT03686241 |
Recruiting |
The Use of a Dynamic Compression Intramedullary Nail for Tibiotalocalcaneal Arthrodesis |
- Ankle Arthritis
- Foot Arthritis
|
- Procedure: Tibiotalocalcaneal (TTC) arthrodesis
- Device: DynaNail
|
Observational
|
|
- MedShape, Inc
- Saint Alphonsus Medical Group
|
Industry / Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Fusion
- Pain - VAS
- Function - SF-36
- Function - FAAM
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT03686241 |
SARMC-SPS207720 |
|
May 22, 2017 |
May 2022 |
May 2022 |
September 26, 2018 |
September 28, 2018 |
|
- Saint Alphonsus Medical Group Orthopedics Coughlin Foot and Ankle Clinic
Boise, Idaho, United States
|
|
| 5 |
NCT03623100 |
Recruiting |
Neural Indices of Intervention Outcomes in Children With Speech Sound Disorders |
|
- Behavioral: Speech Production Treatment.
- Behavioral: Speech Production + Speech Perception Treatment.
|
Interventional
|
Not Applicable |
- Idaho State University
- National Institute on Deafness and Other Communication Disorders (NIDCD)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change from baseline treated sound production accuracy at four months
- Change from baseline Mismatch Negativity (MMN) mean amplitude at four months
- Change from baseline P1/P2 mean amplitude at four months
- (and 4 more...)
|
60 |
All |
4 Years to 6 Years (Child) |
NCT03623100 |
R15DC013359
7R15DC013359 |
|
August 1, 2014 |
July 31, 2022 |
July 31, 2025 |
August 9, 2018 |
February 25, 2019 |
|
- Idaho State University - Meridian
Meridian, Idaho, United States
|
|
| 6 |
NCT03613818 |
Completed |
Efficacy of a Web-Based Alcohol Intervention for High School Students |
|
- Behavioral: eCHECKUP TO GO
|
Interventional
|
Not Applicable |
- Boise State University
- National Institutes of Health (NIH)
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Reduce Alcohol Use of High School Seniors
- Reduce Alcohol-Related Consequences of High School Seniors
|
313 |
All |
16 Years to 18 Years (Child, Adult) |
NCT03613818 |
023880
R21AA023880 |
|
October 1, 2018 |
March 15, 2019 |
March 15, 2019 |
August 3, 2018 |
April 9, 2019 |
|
- Boise State University
Boise, Idaho, United States
|
|
| 7 |
NCT03613662 |
Completed |
A Research Study to Characterize the Pharmacodynamics and Safety of Repeat Dose SP-102 |
- Lumbosacral Radicular Pain
|
|
Interventional
|
Phase 1 |
- Semnur Pharmaceuticals, Inc.
- Worldwide Clinical Trials
- Scilex Pharmaceuticals, Inc.
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in plasma cortisol in mcg/dL
- Change of white blood cell counts in 10^3/mcL
- Change in blood glucose in mg/dL
|
19 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03613662 |
SP-102-03 |
|
July 13, 2018 |
March 15, 2019 |
March 15, 2019 |
August 3, 2018 |
March 20, 2019 |
|
- Semnur Research Site 1
Boise, Idaho, United States
|
|
| 8 |
NCT03440073 |
Completed |
Intervention for Pregnancy Related Pain |
- Other Specified Pregnancy-Related Conditions
|
- Other: Mulligan Concept Intervention
- Other: Sham Mulligan Concept Treatment
|
Interventional
|
Not Applicable |
- University of Idaho
- National Institutes of Health (NIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- 3-D motion Analysis- sit to stand
- 3-D Motion Analysis- gait
- 3-D Motion Analysis- active straight leg raise
- (and 7 more...)
|
36 |
Female |
20 Years to 45 Years (Adult) |
NCT03440073 |
17-042
18-22QR-UI-PG76 |
|
January 10, 2018 |
May 30, 2018 |
May 30, 2018 |
February 20, 2018 |
October 23, 2018 |
|
- Integrated Sport Medicine and Rehabilitative Therapy Clinic
Moscow, Idaho, United States
|
|
| 9 |
NCT02940587 |
Withdrawn |
Effectiveness of Aurix Therapy in Venous Leg Ulcers |
|
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time to Heal
- Proportion of wounds healed
- Change in Quality of Life with Chronic Wounds (W-QOL) Score
|
0 |
All |
18 Years and older (Adult, Older Adult) |
NCT02940587 |
CM003 Gold |
|
February 2015 |
February 2018 |
February 2018 |
October 21, 2016 |
October 21, 2016 |
|
- St. Luke's Intermountain Research
Boise, Idaho, United States
|
|
| 10 |
NCT02930642 |
Recruiting |
Food Insecurity, Obesity, and Impulsive Food Choice |
- Feeding Behavior
- Obesity
- Impulsivity
|
- Behavioral: Mindful Eating
- Other: Nutrition DVD
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of impulsive choices as assessed by the Food Choice Questionnaire
- Number of impulsive choices as assessed by the Monetary Choice Questionnaire
|
120 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02930642 |
IdahoSU001 |
FIOI |
May 31, 2017 |
May 31, 2020 |
May 31, 2020 |
October 12, 2016 |
August 7, 2019 |
|
- Idaho State University
Pocatello, Idaho, United States
|
|
| 11 |
NCT02921009 |
Recruiting |
McNeel Eye Center Corneal Crosslinking Study |
|
- Device: Crosslinking using UV light of two different fluence rates
|
Interventional
|
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Post treatment topographic analysis of Crosslinked patients
- Post Treatment Best Corrected Visual Acuity
|
100 |
All |
15 Years to 50 Years (Child, Adult) |
NCT02921009 |
MEC CxL Transepithelial |
|
September 2016 |
December 2020 |
December 2020 |
September 30, 2016 |
March 13, 2019 |
|
- McNeel Eye Center
Boise, Idaho, United States
|
|
| 12 |
NCT02912351 |
Recruiting |
A Post-Market Retrospective Study on Revision Total Knee Arthroplasty Using Medacta GMK® Revision Prosthesis |
|
- Other: Patient record review, Radiographs, and questionaires.
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Total Knee Society Scores (KSS)
- Radiographic Analysis
- Patient Satisfaction
- Complication Assessment
|
50 |
All |
Child, Adult, Older Adult |
NCT02912351 |
K102437-01 |
|
January 2017 |
December 2021 |
December 2021 |
September 23, 2016 |
October 16, 2019 |
|
- Saint Alphonsus Medical Group
Boise, Idaho, United States
|
|
| 13 |
NCT02900248 |
Terminated |
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice |
- Neoplasms
- Lung Neoplasms
- Colon Neoplasms
- (and 22 more...)
|
- Other: Provider determined
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Best Overall Response
- Time to Treatment Progression
- Overall Survival
- (and 2 more...)
|
23 |
All |
18 Years and older (Adult, Older Adult) |
NCT02900248 |
N1OR |
N1 |
October 2, 2017 |
March 29, 2019 |
March 29, 2019 |
September 14, 2016 |
April 2, 2019 |
|
- Teton Cancer Institute
Idaho Falls, Idaho, United States
|
|
| 14 |
NCT02632929 |
Active, not recruiting |
Prevention of Amputation in Diabetic Foot Ulcers Using Amniotic Tissue |
|
|
Observational
|
|
- Boise VA Medical Center
- Integra LifeSciences Corporation
|
U.S. Fed / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Limb salvage
- effective wound healing
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT02632929 |
00816 |
|
July 2015 |
July 2019 |
December 2019 |
December 17, 2015 |
July 16, 2019 |
|
- Boise VAMC
Boise, Idaho, United States
|
|
| 15 |
NCT02363907 |
Completed
Has Results |
Observational Study to Evaluate the Effectiveness and Safety of the Dexcom G4 Continuous Glucose Monitoring System in Pediatrics |
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Point Accuracy of CGM ISF Readings to Blood Glucose Measured by a Reference Device
|
30 |
All |
2 Years to 17 Years (Child) |
NCT02363907 |
PTL-900982 |
|
September 2012 |
October 2012 |
October 2012 |
February 16, 2015 |
July 27, 2017 |
July 27, 2017 |
- Rocky Mountain Diabetes and Osteoporosis Center
Idaho Falls, Idaho, United States
|
|
| 16 |
NCT02330445 |
Completed |
6-Month Phase I/II Open Label PRTX-100 in Previous Rheumatoid Arthritis Study Participants and Sera Collection |
|
|
Interventional
|
Phase 1
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety (Analysis of Adverse Events)
- ACR-28 joint count
- Patient's global assessment of disease activity
- (and 14 more...)
|
13 |
All |
18 Years and older (Adult, Older Adult) |
NCT02330445 |
PRTX-100-105 |
SPARTA-II |
February 2015 |
April 18, 2016 |
November 30, 2016 |
January 5, 2015 |
October 16, 2018 |
|
- Protalex Investigational Site
Coeur d'Alene, Idaho, United States
|
|
| 17 |
NCT02230085 |
Completed
Has Results |
Adherence Risk Indicator Validation Study |
|
- Other: Administration of the questionnaire and monitoring of CPAP adherence
|
Observational
|
|
- Fisher and Paykel Healthcare
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
110 |
All |
18 Years and older (Adult, Older Adult) |
NCT02230085 |
CIA-121 |
ARI |
September 2014 |
August 2015 |
December 2015 |
September 3, 2014 |
March 3, 2017 |
December 2, 2016 |
- EverythingCPAP
Boise, Idaho, United States
|
|
| 18 |
NCT02185001 |
Terminated |
Repair of Medial Patellofemoral Ligament Compared to Conservative Treatment for First Time Patella Dislocation |
- Dislocated Patella
- Torn Medial Patellofemoral Ligament
|
- Procedure: Direct Medial Patellofemoral Ligament (MPFL) Repair
- Procedure: Physical therapy
|
Interventional
|
Not Applicable |
- Orthopedic Specialty Institute
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Patient Reported Change in Patellar Stability, Subluxation, or Recurrent Dislocation.
- Subjective Outcome Measurement (Kujala Test)
|
2 |
All |
10 Years and older (Child, Adult, Older Adult) |
NCT02185001 |
TLKC-0001 |
|
October 2014 |
March 2016 |
March 2016 |
July 9, 2014 |
March 9, 2017 |
|
- The Lyman Knee Clinic
Coeur d'Alene, Idaho, United States
|
|
| 19 |
NCT02170558 |
Withdrawn |
Enhanced Metal Reduction Techniques for Definitive CT Scanning to Assess Spinal Fusion With TM-Ardis |
- Degenerative Disc Disease
|
- Device: TM- Ardis implant and Metal Reduction CT software
|
Observational
|
|
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- CT scan to determine if the study software can reduce metal scatter on the scan.
|
0 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT02170558 |
CSU2013-05S |
|
June 2014 |
December 2015 |
December 2015 |
June 23, 2014 |
January 24, 2019 |
|
- St Alphonsus Regional Medical Center
Boise, Idaho, United States
|
|
| 20 |
NCT02121769 |
No longer available |
Omegaven Expanded Access Protocol |
- Parenteral Nutrition Associated Liver Disease
|
|
Expanded Access
|
|
- St. Luke’s Health System, Boise, Idaho
|
Other |
|
|
|
All |
up to 17 Years (Child) |
NCT02121769 |
Omegaven Expanded Access |
|
|
|
|
April 24, 2014 |
April 10, 2019 |
|
- St. Luke's Pediatric Gastroenterology
Boise, Idaho, United States
|
|
| 21 |
NCT02091804 |
Unknown † |
Beginning Relationships in a Native Community |
|
- Behavioral: Immediate Group
- Behavioral: Wait-List group
|
Interventional
|
Not Applicable |
- University of Washington
- National Institute on Minority Health and Health Disparities (NIMHD)
- Washington State University
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Other
|
- Change in Quality of caregiver-child interactions from baseline at 3 months and 6 months
- Change in Caregiver helplessness from baseline at 3 months and 6 months
- Change in Caregiver stress from baseline at 3 months and 6 months
- Change in Child Social-emotional Competence from baseline at 3 months and 6 months
|
34 |
All |
Child, Adult, Older Adult |
NCT02091804 |
45360
1P20MD006871 |
P20-RP3 |
September 2014 |
May 2017 |
May 2018 |
March 19, 2014 |
October 26, 2017 |
|
- Nimiipuu Health Community Clinic
Lapwai, Idaho, United States
|
|
| 22 |
NCT01544283 |
Unknown † |
Pain Patch Versus Injections in the Treatment of Pain Associated With Shoulder Impingement Syndrome |
|
- Drug: Synera® (lidocaine 70 mg and tetracaine 70 mg) topical patch
- Drug: Triamcinolone Acetonide
|
Interventional
|
Phase 2 |
- Injury Care Medical Center
- Nuvo Research Inc.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pain Intensity
- Patient Global Assessment of Treatment Satisfaction
- Patient Global Impression of Change
- (and 2 more...)
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT01544283 |
NS001 |
|
March 2012 |
January 2014 |
March 2014 |
March 5, 2012 |
March 6, 2012 |
|
- Injury Care Medical Center
Boise, Idaho, United States
|
|
| 23 |
NCT01514305 |
Completed |
Observational Study to Evaluate the Effectiveness and Safety Study of the Dexcom G4™ Continuous Glucose Monitoring System |
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Absolute Relative Difference (%) to Reference Standard
|
21 |
All |
18 Years and older (Adult, Older Adult) |
NCT01514305 |
PTL900830 |
|
November 2011 |
December 2011 |
December 2011 |
January 23, 2012 |
January 23, 2012 |
|
- Rocky Mountain Diabetes and Osteoporosis Center
Idaho Falls, Idaho, United States
|
|
| 24 |
NCT01341067 |
Completed
Has Results |
Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes |
|
|
Observational
|
|
- Rocky Mountain Diabetes and Osteoporosis Center
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Change in HgbA1c
- Percentage of Time Spent at Glycemic Levels <65 mg/dl
- Change in Percentage of Time Spent at Glycemic Levels >180 mg/dl
- Change in Basal Insulin Dose From Baseline Values
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT01341067 |
RMDC-001 |
DexlonT2 |
April 2011 |
December 2011 |
December 2011 |
April 25, 2011 |
May 2, 2014 |
May 2, 2014 |
- Rocky Mountain Diabetes and Osteoporosis Center
Idaho Falls, Idaho, United States
|
|
| 25 |
NCT01084824 |
Completed |
A Trial Examining the Treatment of Common Warts With Combination Liquid Nitrogen (LN2) and Cantharidin |
|
- Drug: Liquid nitrogen and cantharidin
- Drug: Liquid nitrogen and topical placebo
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage of common warts cleared
|
70 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01084824 |
NID-001 |
|
June 2007 |
June 2008 |
September 2008 |
March 11, 2010 |
March 11, 2010 |
|
- North Idaho Dermatology
Coeur D'Alene, Idaho, United States
|
|
| 26 |
NCT01055444 |
Completed |
Study Evaluating Heated Lidocaine/Tetracaine Topical Patch in Treatment of Patients With Shoulder Impingement Syndrome |
- Shoulder Impingement Syndrome
|
- Drug: Heated lidocaine and tetracaine topical patch
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pain intensity
- Pain interference with activities (general, normal work, and sleep)
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT01055444 |
SC-202 |
|
March 2010 |
August 2010 |
September 2010 |
January 25, 2010 |
March 16, 2012 |
|
- Injury Care Medical Center
Boise, Idaho, United States
|
|
| 27 |
NCT00925353 |
Completed
Has Results |
The Pharmacokinetics of 4% Lidocaine Gel When Applied Topically to the Breasts |
|
|
Interventional
|
Phase 4 |
- Mountain States Tumor and Medical Research Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pharmacokinetic Parameters Based on Plasma Concentration of Lidocaine and MEGX in Nanograms/Milliliter.
- EKG Changes
- Variation of Heart Rate (Bpm), Respiratory Rate (Respirations Per Minute, Rpm), Systolic Blood Pressure (mm Hg), and Diastolic Blood Pressure (mm Hg) Over Time.
- Frequencies of Moderate, Severe, or Life-threatening Side Effects
|
13 |
Female |
35 Years and older (Adult, Older Adult) |
NCT00925353 |
MSTMRI-002 |
|
January 2010 |
February 2010 |
February 2010 |
June 22, 2009 |
December 23, 2013 |
December 23, 2013 |
- St. Luke's Mountain States Tumor Institute
Boise, Idaho, United States
|
|
| 28 |
NCT00780741 |
Completed
Has Results |
Immediate Office Probing vs Deferred Facility Probing for Nasolacrimal Duct Obstruction in Children 6 to <10 Months Old |
- Nasolacrimal Duct Obstruction
|
- Procedure: Immediate Office Probing
- Procedure: Deferred Facility Probing
|
Interventional
|
Phase 3 |
- Jaeb Center for Health Research
- National Eye Institute (NEI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of Participants With Treatment Success
- Cost of Treatment
- Months of Symptoms of Nasolacrimal Duct Obstruction (NLDO) Between Randomization and 18 Months of Age
- (and 2 more...)
|
220 |
All |
6 Months to 10 Months (Child) |
NCT00780741 |
NEI-142
2U10EY011751 |
NLD3 |
October 2008 |
November 2011 |
January 2012 |
October 28, 2008 |
June 24, 2016 |
November 12, 2012 |
- Intermountain Eye Centers
Boise, Idaho, United States
|
|
| 29 |
NCT00426933 |
Completed |
Phase 2 Safety and Efficacy Study of Daptomycin in Complicated Skin and Skin Structure Infections |
|
- Drug: Daptomycin
- Drug: Vancomycin
|
Interventional
|
Phase 2 |
- Cubist Pharmaceuticals LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical Response Rate at TOC
- difference between clinical response rates at EOT
- microbiological eradication rates
|
100 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT00426933 |
DAP-HDSD-06-01 |
|
January 2007 |
September 2007 |
September 2007 |
January 25, 2007 |
September 14, 2010 |
|
- Idaho Falls Infectious Diseases, PLLC
Idaho Falls, Idaho, United States
|
|
| 30 |
NCT00382083 |
Completed |
Premedication to Reduce Discomfort With Screening Mammography |
|
- Drug: 1000 mg acetaminophen
- Drug: 800 mg ibuprofen
- Drug: 1 oz 4% lidocaine gel
|
Interventional
|
Phase 4 |
- Mountain States Tumor and Medical Research Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Discomfort scores on a visual analog scale at recruitment, at enrollment, and after mammogram
- Satisfaction scores on a visual analog scale after mammogram
- Pre-mammogram anxiety scores on a visual anxiety scale at enrollment
- Pre-mammogram breast tenderness scores on a visual analog scale at enrollment
|
|
Female |
30 Years and older (Adult, Older Adult) |
NCT00382083 |
MSTMRI - 001 |
|
March 2006 |
|
June 2006 |
September 28, 2006 |
September 28, 2006 |
|
- St. Luke's Mountain States Tumor Institute Breast Cancer Detection Center
Boise, Idaho, United States
|
|
| 31 |
NCT03632759 |
Recruiting |
Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D |
|
- Drug: Liraglutide
- Drug: Golimumab
|
Interventional
|
Early Phase 1 |
- Carla Greenbaum, MD
- Juvenile Diabetes Research Foundation
- Benaroya Research Institute
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Proportion of individuals with peak MMTT stimulated C-peptide >0.017 pmol/mL.
|
30 |
All |
18 Years to 50 Years (Adult) |
NCT03632759 |
IRB18-044 |
|
August 15, 2018 |
April 2020 |
June 2020 |
August 15, 2018 |
April 15, 2019 |
|
- Rocky Mountain Diabetes and Osteoporosis Center
Idaho Falls, Idaho, United States - Benaroya Research Institute
Seattle, Washington, United States
|
|
| 32 |
NCT02925442 |
Active, not recruiting |
Genicular Radiofrequency Ablation for Unilateral Knee Arthroplasty Pain Management |
- Osteoarthritis of the Knee
|
- Procedure: t-RFA
- Procedure: C-RFA
- Procedure: Control
|
Interventional
|
Not Applicable |
- Lyman Medical Research Foundation, Inc.
- Halyard Health
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Postoperative analgesic consumption
- Hospital Length of Stay (LOS)
- Pain Score
|
150 |
All |
40 Years and older (Adult, Older Adult) |
NCT02925442 |
OSI-0002 |
RFA |
January 25, 2017 |
January 7, 2020 |
February 7, 2020 |
October 5, 2016 |
May 24, 2019 |
|
- Orthopedic Specialty Institute
Coeur d'Alene, Idaho, United States - Orthopedic Specialty Institute
Spokane, Washington, United States
|
|
| 33 |
NCT02021955 |
Completed |
Integrating Care After Exacerbation of COPD |
- Chronic Obstructive Pulmonary Disease
|
- Behavioral: guideline treatment recommendations
|
Interventional
|
Not Applicable |
- VA Office of Research and Development
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- hospital re-admission and mortality
- patient quality-of-life
|
362 |
All |
Child, Adult, Older Adult |
NCT02021955 |
IIR 12-130 |
InCasE |
February 11, 2015 |
November 29, 2018 |
January 31, 2019 |
December 27, 2013 |
March 8, 2019 |
|
- Boise VA Medical Center, Boise, ID
Boise, Idaho, United States - VA Puget Sound Health Care System Seattle Division, Seattle, WA
Seattle, Washington, United States
|
|
| 34 |
NCT01839864 |
Withdrawn |
Utilizing a Promotora Model for Rural Adult Hispanics Diagnosed With Metabolic Syndrome: A Clinical Trial |
|
- Behavioral: Promotora plus standard physical screening exam , hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count
|
Interventional
|
Not Applicable |
- Family Medicine Residency of Idaho
- Mountain States Group
- Saint Alphonsus Medical Group
- Quantified, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: Triple (Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Patient Activation Measure from baseline to six months and six months to one year
- Changes in patient attitudes about providers and carefrom baseline to six months and six months to one year
|
0 |
All |
18 Years and older (Adult, Older Adult) |
NCT01839864 |
FMRI Promotora Trial |
FMRIMetSynd |
September 2013 |
June 2016 |
August 2016 |
April 25, 2013 |
February 14, 2017 |
|
- Saint Alphonsus Medical Group Caldwell Clinic
Caldwell, Idaho, United States - Saint Lukes Clinic Jerome
Jerome, Idaho, United States - St Alphonsus Medical Group Nampa Clinic
Nampa, Idaho, United States
|
|
| 35 |
NCT02109107 |
Completed
Has Results |
Study of Low Level Laser Light Therapy on Circumference Reduction |
|
- Device: Erchonia EZ6 Laser
|
Interventional
|
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Combined Circumference Measurements
- Change in Body Weight
- Change in Body Mass Index (BMI)
- Subject Satisfaction With Study Outcome Rating
|
54 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02109107 |
EC_EZ6_BC_001 |
|
October 2013 |
November 2014 |
November 2014 |
April 9, 2014 |
February 2, 2016 |
February 2, 2016 |
- Advanced Gynecology Specialists of Augusta, LLC
Evans, Georgia, United States - CT Dermatology PC
Fruitland, Idaho, United States
|
|
| 36 |
NCT01835743 |
Completed
Has Results |
Study of Low Level Laser Therapy to Treat Chronic Heel Pain Arising From Plantar Fasciitis |
|
- Device: Erchonia HPS Laser
- Device: Placebo Laser
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of Participants Who Attained a Change of -30% or Greater in the VAS Score
- Change in Heel Pain Score on the Visual Analog Scale (VAS)
|
69 |
All |
18 Years and older (Adult, Older Adult) |
NCT01835743 |
EC_HP_001 |
|
February 2012 |
May 2012 |
May 2013 |
April 19, 2013 |
June 3, 2014 |
June 3, 2014 |
- Arizona Institute of Footcare Physicians
Mesa, Arizona, United States - Coughlin Foot and Ankle Clinic
Boise, Idaho, United States
|
|
| 37 |
NCT01704157 |
Completed |
A Prospective Study Evaluating the Treatment of Knee Osteoarthritis With the Cryo-Touch III Device |
- Osteoarthritis of the Knee
|
|
Interventional
|
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- An improvement in the Visual Analog Scale (VAS) for pain at Day 7
- Improvement (pain, stiffness, and functionality) as determined by WOMAC Scale at Day 7.
- Duration of Treatment Effect
- Analgesic Use
|
33 |
All |
18 Years and older (Adult, Older Adult) |
NCT01704157 |
MYO-0601
Pain-OA |
|
September 2012 |
April 2013 |
July 2013 |
October 11, 2012 |
January 29, 2014 |
|
- Neurovations
Napa, California, United States - Injury Care Medical Center
Boise, Idaho, United States
|
|
| 38 |
NCT00129831 |
Completed |
Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD) |
|
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety variables (laboratory tests, ECG, adverse events)
- Lung function tests
- Pharmacokinetics
|
6 |
All |
40 Years to 75 Years (Adult, Older Adult) |
NCT00129831 |
CQAB149B2202 |
|
September 2004 |
September 2005 |
September 2005 |
August 12, 2005 |
October 25, 2011 |
|
- Radiant Research
Encinitas, California, United States - Radiant Research
Boise, Idaho, United States
|
|
| 39 |
NCT03015805 |
Recruiting |
Teen Success Project |
|
- Behavioral: Contingency Management
- Behavioral: Probation as Usual
|
Interventional
|
Not Applicable |
- Oregon Social Learning Center
- George Mason University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Changes from Baseline scores compared to 9 months post-Baseline Urine Drug Screens (measured at 0, 3, 6 and 9 months).
- Changes from Baseline scores compared to 9 months post-Baseline Substance Use and Problems (measured at 0, 3, 6 and 9 months).
- Changes in number and severity of criminal charges in official records in the 18 months pre-Baseline compared with 18 months post-Baseline.
- (and 8 more...)
|
540 |
All |
12 Years to 17 Years (Child) |
NCT03015805 |
R01DA041434-01 |
JPO-CM |
October 1, 2017 |
November 2019 |
February 2022 |
January 10, 2017 |
August 28, 2019 |
|
- Mini-Cassia Juvenile Probation
Rupert, Idaho, United States - Twin Falls Juvenile Probation
Twin Falls, Idaho, United States - Washoe County Juvenile Probation
Reno, Nevada, United States
|
|
| 40 |
NCT02351115 |
Completed |
Staccato Alprazolam and Photoparoxysmal Response |
|
- Drug: Staccato® Alprazolam, 0.5 mg
- Drug: Staccato® Alprazolam, 1 mg
- Drug: Staccato® Alprazolam, 2 mg
- (and 2 more...)
|
Interventional
|
Phase 2 |
- Alexza Pharmaceuticals, Inc.
- The Epilepsy Study Consortium
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in the photosensitivity response in subjects receiving Staccato® Alprazolam as compared to placebo
- Assessment of sedation using 2 visual analogue scales
- Correlation of plasma concentrations of Staccato® Alprazolam with pharmacodynamic effects on photosensitivity response
- Correlation of plasma concentrations of Staccato® Alprazolam with pharmacodynamic effects on sedation
|
5 |
All |
18 Years to 60 Years (Adult) |
NCT02351115 |
AMDC-002-202 |
|
January 2015 |
March 2016 |
March 2016 |
January 30, 2015 |
March 15, 2017 |
|
- Consultants in Epilepsy & Neurology, PLLC
Boise, Idaho, United States - New York University Epilepsy Center
New York, New York, United States - University of Pennsylvania - Penn Epilepsy Center
Philadelphia, Pennsylvania, United States
|
|
| 41 |
NCT01831960 |
Completed |
An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne Vulgaris |
|
- Drug: cortexolone 17α-propionate
|
Interventional
|
Phase 2 |
- Intrepid Therapeutics, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in HPA Axis Response to Cosyntropin
- Change in PK profiles of cortexolone 17α-propionate and cortexolone
|
42 |
All |
12 Years and older (Child, Adult, Older Adult) |
NCT01831960 |
171-7151-202 |
|
April 2013 |
November 2013 |
November 2013 |
April 15, 2013 |
April 16, 2015 |
|
- Northwest Clinical Trials, Inc.
Boise, Idaho, United States - Shideler Clinical Research Center
Carmel, Indiana, United States - Michigan Center for Research Corp.
Clinton Township, Michigan, United States
|
|
| 42 |
NCT01175889 |
Unknown † |
Megadyne Ace Incision/Dissection Study |
- Abdominoplasty
- Bilateral Breast Reduction
- Bilateral Breast Lift
- (and 2 more...)
|
- Device: E-Z Clean ACE Blade
|
Interventional
|
Phase 4 |
- Megadyne Medical Products Inc.
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Evaluate Wound Healing/Scar Formation
- Evaluate patient satisfaction relating to wound healing
|
52 |
All |
18 Years to 60 Years (Adult) |
NCT01175889 |
ACE MS 1 |
ACE |
August 2010 |
December 2012 |
December 2012 |
August 5, 2010 |
October 25, 2012 |
|
- Center for Plastic Surgery
Twin Falls, Idaho, United States - Southwest Surgical Suites, LLC
Fort Wayne, Indiana, United States - Plastic and Reconstructive Surgery University Health Sciences
Winston-Salem, North Carolina, United States
|
|
| 43 |
NCT04056299 |
Recruiting |
Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy |
|
- Biological: AR201 Powder
- Biological: Placebo powder
|
Interventional
|
Phase 2 |
- Aimmune Therapeutics, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Efficacy of AR201 in a CODIT regimen in hen egg-allergic subjects aged 4 to 26 years, inclusive, assessed by single highest tolerated dose of at least 1000 mg dried egg white protein in a DBPCFC
- Safety and tolerability of AR201
|
84 |
All |
4 Years to 26 Years (Child, Adult) |
NCT04056299 |
AIME01 |
|
August 2019 |
March 1, 2021 |
March 1, 2021 |
August 14, 2019 |
August 14, 2019 |
|
- Peninsula Research Associates
Rolling Hills Estates, California, United States - Allergy and Asthma Clinical Research
Walnut Creek, California, United States - Idaho Allergy, LLC dba Idaho Research
Eagle, Idaho, United States
|
|
| 44 |
NCT00860093 |
Terminated |
Efficacy and Safety of Using MPC-5971 in Subjects Undergoing Shock Wave Lithotripsy |
|
- Other: placebo
- Drug: MPC-5971
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- stone free rate after SWL treatment
- increase in urine inhibitors
- Reduced need for secondary procedures such as URS to clear obstructive fragments
- reduced stone/fragment area (mm2),percent change from the treatment stone area (mm2)
|
135 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT00860093 |
MPC-5971 |
|
April 2010 |
November 2010 |
December 2010 |
March 11, 2009 |
March 7, 2019 |
|
- Idaho Urologic Institute
Meridian, Idaho, United States - Columbus Urology Research
Columbus, Ohio, United States - Urology Clinics of North Texas, PA
Dallas, Texas, United States
|
|
| 45 |
NCT03502174 |
Completed |
FreeStyle Libre Glucose Monitoring System in Pediatric Populations |
|
- Device: FreeStyle Libre Flash Glucose Monitoring System
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- FreeStyle Libre Flash Glucose Monitoring System Performance
- FreeStyle Libre Flash Glucose Monitoring System Related adverse device effects
|
63 |
All |
6 Years to 17 Years (Child) |
NCT03502174 |
ADC-US-VAL-18172 |
|
April 5, 2018 |
July 3, 2018 |
July 3, 2018 |
April 18, 2018 |
January 28, 2019 |
|
- Sansum Diabetes Research Institute
Santa Barbara, California, United States - Diablo Clinical Research
Walnut Creek, California, United States - Rocky Mountain Diabetes & Osteoporosis Center
Idaho Falls, Idaho, United States
|
|
| 46 |
NCT01753765 |
Completed |
Study Evaluating the Treatment of Occipital Neuralgia |
|
- Device: Device: Cryo-Touch III Study treatment at Day 0.
|
Interventional
|
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- A reduction in either pain frequency or severity associated with occipital neuralgia.
- Duration of treatment
- Analgesic use
- Safety Events
|
26 |
All |
18 Years and older (Adult, Older Adult) |
NCT01753765 |
MYO-0613 |
|
October 2012 |
December 2013 |
July 2014 |
December 20, 2012 |
October 21, 2015 |
|
- Neurovations
Napa, California, United States - Injury Care Medical Center
Boise, Idaho, United States - International Clinical Research
Overland Park, Kansas, United States
|
|
| 47 |
NCT00328445 |
Completed |
Randomized Trial of the Positive Action Program in Hawaii Schools |
- Character
- Violence
- Substance Use
- (and 2 more...)
|
- Behavioral: Positive Action
|
Interventional
|
Not Applicable |
- National Institute on Drug Abuse (NIDA)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Self-reported attitudes and behaviors
- Teacher reports of behaviors
- Parent reports of student behaviors
- (and 3 more...)
|
2500 |
All |
6 Years and older (Child, Adult, Older Adult) |
NCT00328445 |
R01DA013474 |
|
April 2001 |
June 2006 |
June 2006 |
May 22, 2006 |
January 12, 2017 |
|
- Positive Action, Inc.
Twin Falls, Idaho, United States - University of Illinois at Chicago
Chicago, Illinois, United States - Oregon State University
Corvallis, Oregon, United States
|
|
| 48 |
NCT00717522 |
Terminated
Has Results |
Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma |
|
|
Interventional
|
Phase 2 |
- Celgene Corporation
- Celgene
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, or Discontinuations Due to AEs
- Tumor Response as Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee Guidelines
|
7 |
All |
18 Years and older (Adult, Older Adult) |
NCT00717522 |
CC-4047-STSAR-001 |
|
August 2008 |
January 2009 |
January 2009 |
July 17, 2008 |
April 16, 2013 |
April 16, 2013 |
- Sarcoma Oncology Center
Santa Monica, California, United States - Kootenai Cancer Center
Couer D' Alene, Idaho, United States - Nebraska Methodist Hospital
Omaha, Nebraska, United States
|
|
| 49 |
NCT03445013 |
Completed |
A Study Assessing the PK, PD, Safety, and Tolerability of SB414 in Psoriasis |
|
- Drug: SB414 6%
- Drug: Vehicle
|
Interventional
|
Phase 1 |
- Novan, Inc.
- Novella Clinical
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Plasma concentrations of hMAP3
- Safety Profile (Reported Adverse Events)
- Subject Assessment of Tolerability
- (and 4 more...)
|
36 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03445013 |
NI-PS101 |
|
October 13, 2017 |
January 31, 2018 |
February 6, 2018 |
February 26, 2018 |
March 27, 2018 |
|
- Novella Site# 247
Boise, Idaho, United States - Novella Site# 183
Austin, Texas, United States - Novella Site# 249
College Station, Texas, United States - Novella Site# 114
Norfolk, Virginia, United States
|
|
| 50 |
NCT02375815 |
Completed |
Statin Choice Decision Aid Implementation First Phase |
- Cardiovascular Factor Risk
|
- Other: Statin Choice Implementation
|
Interventional
|
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Effective Implementation of Statin Choice Decision Aid (SCDA), as indicated by the cumulative reach (% usage in appropriate primary care consultations) across all 3 health systems (as measured by EMR-based calculations).
|
313 |
All |
18 Years and older (Adult, Older Adult) |
NCT02375815 |
14-006048 |
SCIP1 |
January 2015 |
December 2016 |
March 2017 |
March 3, 2015 |
March 24, 2017 |
|
- Kootenai Health
Coeur d'Alene, Idaho, United States - Mayo Clinic in Rochester
Rochester, Minnesota, United States - Mosaic Life Care
St. Joseph, Missouri, United States - Altru Health System
Grand Forks, North Dakota, United States
|
|
| 51 |
NCT04040816 |
Recruiting |
Placebo Controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients |
|
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Incidence of Treatment-Emergent Adverse Events
- Cmax
- tmax
- (and 12 more...)
|
60 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT04040816 |
SAP001-1-002 |
|
January 1, 2019 |
June 2020 |
June 2020 |
August 1, 2019 |
August 1, 2019 |
|
- Miami Research Associates
South Miami, Florida, United States - Advanced Clinical Research
Meridian, Idaho, United States - Vince & Associates Clinical Research, Inc.
Overland Park, Kansas, United States - M3 Wake Research, Inc
Raleigh, North Carolina, United States
|
|
| 52 |
NCT03382405 |
Active, not recruiting |
Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults |
- Cytomegalovirus Infection
|
- Biological: mRNA-1647
- Biological: mRNA-1443
- Other: Placebo
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Frequency of solicited AEs (local and systemic reactogenicity events)
- Frequency of unsolicited adverse events
- Frequency of medically-attended AEs, adverse events of special interest (AESI), and serious adverse events (SAE)
- (and 5 more...)
|
181 |
All |
18 Years to 49 Years (Adult) |
NCT03382405 |
mRNA-1647/mRNA-1443-P101 |
|
November 13, 2017 |
July 2020 |
July 2020 |
December 22, 2017 |
August 28, 2019 |
|
- Research Centers of America
Hollywood, Florida, United States - Advanced Clinical Research
Meridian, Idaho, United States - Optimal Research
Peoria, Illinois, United States - Johnson County Clinical Trials
Lenexa, Kansas, United States
|
|
| 53 |
NCT02696252 |
Completed |
G5® Mobile Continuous Glucose Monitoring System Automated vs. Manual Sensor Applicator |
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- proportion of blood glucose values, compared between CGM and a lab glucose analyzer that are matched relative to a diabetes accuracy measurement of %20/20 mg/dL
|
97 |
All |
2 Years and older (Child, Adult, Older Adult) |
NCT02696252 |
PTL-901800 |
|
January 2016 |
April 2016 |
April 2016 |
March 2, 2016 |
April 14, 2016 |
|
- AMCR Institute
Escondido, California, United States - Rocky Mountain Diabetes and Osteoporosis Center
Idaho Falls, Idaho, United States - Joslin Diabetes Center
Boston, Massachusetts, United States - Clinical Trials of Texas
San Antonio, Texas, United States
|
|
| 54 |
NCT04096274 |
Not yet recruiting |
The Implementation and Sustainment of Digital MBC in Youth Mental Health Services |
- Leadership
- Behavioral Symptoms
|
- Behavioral: Leadership for Organization Change and Implementation (LOCI)
- Behavioral: Leadership webinars
|
Interventional
|
Not Applicable |
- Boise State University
- University of California, San Diego
- University of Central Florida
- (and 2 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Fidelity to MBC
- Youth Outcomes
- Mechanisms of Fidelity
|
720 |
All |
18 Years and older (Adult, Older Adult) |
NCT04096274 |
8424
R01MH119127 |
|
September 23, 2019 |
March 31, 2023 |
March 31, 2023 |
September 19, 2019 |
September 19, 2019 |
|
- University of California, San Diego
San Diego, California, United States - University of Central Florida
Orlando, Florida, United States - Boise State University
Boise, Idaho, United States - University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
|
| 55 |
NCT02248636 |
Completed |
Cholinesterase Inhibitor Discontinuation |
|
- Drug: Cholinesterase inhibitor
- Drug: Sham discontinuation
|
Interventional
|
Phase 2
Phase 3 |
- VA Office of Research and Development
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Successful completion
- Medical events
- Caregiver burden
- (and 4 more...)
|
72 |
All |
60 Years and older (Adult, Older Adult) |
NCT02248636 |
CLIN-014-13F |
CID |
January 22, 2015 |
October 1, 2019 |
October 1, 2019 |
September 25, 2014 |
October 3, 2019 |
|
- Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR
Little Rock, Arkansas, United States - Boise VA Medical Center, Boise, ID
Boise, Idaho, United States - Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA
Bedford, Massachusetts, United States - VA Puget Sound Health Care System Seattle Division, Seattle, WA
Seattle, Washington, United States
|
|
| 56 |
NCT02196818 |
Recruiting |
A Multi-centre, Prospective Surveillance to Assess Mid-term Performance of the Mpact Cup |
- Osteoarthritis
- Arthritis
- Avascular Necrosis
- (and 2 more...)
|
- Device: Mpact Acetabular Shell
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- The Kaplan-Meier analysis as a measure of implant performance.
- The Harris Hip Score.
- Radiological analysis as a meausure of safety.
|
200 |
All |
Child, Adult, Older Adult |
NCT02196818 |
P01.014.08/00 |
|
March 2013 |
August 2024 |
August 2024 |
July 22, 2014 |
August 20, 2019 |
|
- Vail Orthopedics, P.C.
Denver, Colorado, United States - Saint Alphonsus Regional Medical Center
Boise, Idaho, United States - Illinois Bone & Joint Institute, LLC
Libertyville, Illinois, United States - Jordan Valley Medical Center
West Jordan, Utah, United States
|
|
| 57 |
NCT03820050 |
Completed |
FreeStyle LIbre Flash Glucose Monitoring System Pediatric Accuracy Study |
|
- Device: Freestyle LIbre Flash Glucose Monitoring System
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
144 |
All |
4 Years to 17 Years (Child) |
NCT03820050 |
ADC-US-VAL-18175 |
|
January 29, 2019 |
June 14, 2019 |
June 14, 2019 |
January 29, 2019 |
June 18, 2019 |
|
- Sansum Diabetes Research Institute
Santa Barbara, California, United States - Barbara Davis Center for Diabetes
Aurora, Colorado, United States - Rocky Mountain Diabetes and Osteoporosis Center
Idaho Falls, Idaho, United States - Diabetes and Glandular Disease Clinic
San Antonio, Texas, United States
|
|
| 58 |
NCT03257501 |
Completed |
FreeStyle Libre Flash Accuracy Study |
|
- Device: FreeStyle Libre Flash Glucose Monitoring System
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- System Performance with respect to YSI reference venous plasma sample measurements.
- System Related adverse device effects
|
104 |
All |
18 Years and older (Adult, Older Adult) |
NCT03257501 |
ADC-US-VAL-17166 |
|
August 22, 2017 |
January 8, 2018 |
January 8, 2018 |
August 22, 2017 |
January 9, 2018 |
|
- William Sansum Diabetes Center
Santa Barbara, California, United States - Diablo Clinical Research
Walnut Creek, California, United States - Rocky Mountain Diabetes & Osteoporosis Center
Idaho Falls, Idaho, United States - Rainier Clinical Research
Renton, Washington, United States
|
|
| 59 |
NCT03159546 |
Completed |
FreeStyle Libre Flash Glucose Monitoring System Accuracy |
|
- Device: Device: FreeStyle Libre Flash Glucose Monitoring System
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- System Performance
- System Related adverse device effects
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT03159546 |
ADC-US-VAL-17165 |
|
May 13, 2017 |
July 18, 2017 |
August 24, 2017 |
May 18, 2017 |
September 6, 2017 |
|
- William Sansum Diabetes Center
Santa Barbara, California, United States - Diablo Clinical Research
Walnut Creek, California, United States - Rocky Mountain Diabetes & Osteoporosis Center
Idaho Falls, Idaho, United States - Rainier Clinical Research Center
Renton, Washington, United States
|
|
| 60 |
NCT03141892 |
Completed |
FreeStyle Libre Flash Glucose Monitoring System Accuracy Study |
|
- Device: FreeStyle Libre Flash Glucose Monitoring System
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- System Performance
- System related adverse device effects and serious adverse effects
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT03141892 |
ADC-US-VAL-17164 |
|
April 13, 2017 |
May 23, 2017 |
May 30, 2017 |
May 5, 2017 |
July 11, 2017 |
|
- William Sansum Diabetes Center
Santa Barbara, California, United States - Diablo Clinical Research
Walnut Creek, California, United States - Rocky Mountain Diabetes & Osteoporosis Center
Idaho Falls, Idaho, United States - Rainier Clinical Research Center
Renton, Washington, United States
|
|
| 61 |
NCT02662842 |
Completed |
BD FlowSmart™ Subcutaneous Insulin Infusion Set User Preference and Claims Study |
|
- Device: FlowSmart Infusion Set
- Device: Current Infusion Set
|
Observational
|
|
- Becton, Dickinson and Company
- Medtronic
|
Industry |
- Observational Model: Case-Crossover
- Time Perspective: Prospective
|
- Comparative Infusion Set Insertion Pain
- Comparative Infusion Set Wear Comfort
- Overall Infusion Set Preference
|
75 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02662842 |
DBC-15SCARL15 |
|
January 2016 |
February 2016 |
February 2016 |
January 26, 2016 |
April 13, 2017 |
|
- AMCR Institute Inc.
Escondido, California, United States - Atlanta Diabetes Associates
Atlanta, Georgia, United States - Rocky Mountain Diabetes and Osteoporosis Center
Idaho Falls, Idaho, United States - TKL Research
Fair Lawn, New Jersey, United States
|
|
| 62 |
NCT01040858 |
Completed
Has Results |
Cognitive Rehabilitation of Operations Iraqi Freedom and Enduring Freedom (OIF/OEF) Veterans With Cognitive Disorder |
|
- Behavioral: Cognitive Strategy Training
- Other: Placebo comparison group
|
Interventional
|
Not Applicable |
- US Department of Veterans Affairs
- VA Office of Research and Development
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Multiple Sclerosis Neuropsychological Screening Questionnaire-Patient Version
- Prospective-Retrospective Memory Questionnaire (PRMQ; Crawford, Henry, Ward, &
- The Neurobehavioral Symptom Inventory
- (and 9 more...)
|
128 |
All |
18 Years and older (Adult, Older Adult) |
NCT01040858 |
D7217-R
IRB#2277 |
CROVCD |
May 2011 |
May 2013 |
September 2013 |
December 30, 2009 |
January 26, 2015 |
January 26, 2015 |
- VA San Diego Healthcare System, San Diego
San Diego, California, United States - VA Medical Center, Boise
Boise, Idaho, United States - VA Medical Center, Portland
Portland, Oregon, United States - VA Puget Sound Health Care System, Seattle
Seattle, Washington, United States
|
|
| 63 |
NCT00715273 |
Active, not recruiting |
Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication |
- Coronary Artery Disease
- Carotid Artery Diseases
- Atherosclerosis
|
- Drug: Atorvastatin
- Drug: Niacin
- Drug: Colesevelam
- (and 2 more...)
|
Interventional
|
Phase 4 |
- University of Washington
- National Heart, Lung, and Blood Institute (NHLBI)
- Pfizer
- (and 3 more...)
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Other
|
- Changes in carotid plaque composition, as assessed by MRI
- Composite of cardiovascular disease death, non-fatal heart attack, stroke, and worsening ischemia requiring medical interventions
|
217 |
All |
21 Years to 70 Years (Adult, Older Adult) |
NCT00715273 |
STUDY00001165
R01HL063895-05A1 |
CPC |
June 2001 |
March 2019 |
April 2019 |
July 15, 2008 |
February 28, 2019 |
|
- University of Southern California
Los Angeles, California, United States - St. Luke's Idaho Cardiology
Boise, Idaho, United States - University of Washington Coronary Atherosclerosis Research Lab
Seattle, Washington, United States - Yakima Heart Center
Yakima, Washington, United States
|
|
| 64 |
NCT01475760 |
Completed |
A Study to Evaluate Chitosan Chewing Gum in Patients With Chronic Kidney Disease |
|
- Other: K2CG chewing gum (20mg chitosan)
- Other: K2CG chewing gum (60mg chitosan)
|
Interventional
|
Not Applicable |
- Denver Nephrologists, P.C.
- CM&D Pharma Limited
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- serum phosphorus
- salivary phosphorus
|
167 |
All |
18 Years and older (Adult, Older Adult) |
NCT01475760 |
CMD007 |
|
November 2011 |
March 2012 |
March 2012 |
November 21, 2011 |
August 2, 2012 |
|
- Southwest Clinical Reserach Institute, LLC
Tempe, Arizona, United States - Denver Nephrologists, PC
Denver, Colorado, United States - Pacific Renal Research Institute
Meridian, Idaho, United States - Renal Associates, PA
San Antonio, Texas, United States
|
|
| 65 |
NCT01514292 |
Completed
Has Results |
Effectiveness and Safety Study of the Dexcom G4™ Continuous Glucose Monitoring System |
|
- Device: Continuous Glucose Monitoring of glucose levels (Dexcom)
|
Interventional
|
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- CGM Relative Differences to Laboratory Reference
|
72 |
All |
18 Years and older (Adult, Older Adult) |
NCT01514292 |
PTL-900590 |
|
December 2011 |
February 2012 |
February 2012 |
January 23, 2012 |
October 5, 2015 |
October 5, 2015 |
- Profil Institute for Clinical Research
Chula Vista, California, United States - AMCR Institute, Inc.
Escondido, California, United States - Diablo Clinical Research
Walnut Creek, California, United States - Rocky Mountain Diabetes and Osteoporosis Center
Idaho Falls, Idaho, United States
|
|
| 66 |
NCT04115345 |
Recruiting
New |
A Study of a Renal Autologous Cell Therapy (REACT) in Patients With Chronic Kidney Disease (CKD) From Congenital Anomalies of the Kidney and Urinary Tract (CAKUT). |
- Chronic Kidney Disease
- Congenital Anomalies of Kidney and Urinary Tract
|
- Biological: REACT - renal autologous cell therapy
|
Interventional
|
Phase 1 |
- inRegen
- CTI Clinical Trial and Consulting Services
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Assess change in eGFR and observe incidence of renal-specific procedure and/or product related adverse events (AEs) through 24 months following two Renal Autologous Cell Therapy (REACT) injections [Safety].
- Number of subjects with renal-specific adverse events over a 24-month period following injection of Renal Autologous Cell Therapy (REACT).
|
15 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT04115345 |
REGEN-004 |
|
August 13, 2019 |
March 31, 2023 |
May 30, 2023 |
October 4, 2019 |
October 4, 2019 |
|
- Boise Kidney & Hypertension Institute
Boise, Idaho, United States - University of Chicago Medical Center
Chicago, Illinois, United States - Renal Associates of Baton Rouge
Baton Rouge, Louisiana, United States - (and 2 more...)
|
|
| 67 |
NCT03897595 |
Recruiting |
Assess the Mid-term Performance of the Mpact Cup in Subjects Requiring Total Hip Arthroplasty |
|
- Device: Quadra®-H, Quadra®-C, AMIStem®-H or AMIStem®-C femoral stem and Mpact® Acetabular hip system with CoCr Femoral Head or Ceramic MectaCer BIOLOX® Femoral Head
|
Interventional
|
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change from baseline Harris Hip Scores (HHS)
- Change from baseline of implant survivorship
- Change in baseline of Complications
- (and 2 more...)
|
200 |
All |
Child, Adult, Older Adult |
NCT03897595 |
P01.014.08/01 |
|
October 2012 |
December 2022 |
December 2022 |
April 1, 2019 |
October 18, 2019 |
|
- Denver Vail Orthopedics
Parker, Colorado, United States - Saint Alphonsus Medical Group
Boise, Idaho, United States - Illinois Bone and Joint Institute
Libertyville, Illinois, United States - (and 2 more...)
|
|
| 68 |
NCT03686033 |
Suspended |
A Study to Evaluate the Pharmacodynamic Activity of E2082 in Adult Participants With Photosensitive Epilepsy |
|
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Mean Change from Baseline in the PPR Range in the Most Sensitive Eye Condition (Eye Closure, Eyes Closed, or Eyes Open Condition)
- Mean Change from Baseline in PPR Ranges in Each of the 3 Eye Conditions (Eye Closure, Eyes Closed, and Eyes Open Condition)
- Time to Onset of Photosensitivity Response in Each of the 3 Eye Conditions (Eye Closure, Eyes Closed, and Eyes Open Condition)
- (and 9 more...)
|
9 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03686033 |
E2082-A001-201 |
|
October 31, 2018 |
November 18, 2019 |
November 18, 2019 |
September 26, 2018 |
July 26, 2019 |
|
- Clinical Trials, Inc. and Arkansas Epilepsy Program
Little Rock, Arkansas, United States - Consultants in Epilepsy & Neurology, PLLC
Boise, Idaho, United States - Johns Hopkins University- School of Medicine
Baltimore, Maryland, United States - (and 2 more...)
|
|
| 69 |
NCT03603639 |
Terminated |
A Study to Evaluate the Pharmacodynamic Activity of E2730 in Adult Participants With Photosensitive Epilepsy |
|
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Mean Change from Baseline in the Photoparoxysmal Response (PPR) Range in the Most Sensitive Eye Condition
- Mean Change from Baseline in PPR Ranges in Each of the 3 Eye Conditions (Eye Closure, Eyes Closed, and Eyes Open Condition)
- Time to Onset of Photosensitivity Response in all 3 Eye Conditions (Eye Closure, Eyes Closed, and Eyes Open Condition)
- (and 11 more...)
|
25 |
All |
18 Years to 60 Years (Adult) |
NCT03603639 |
E2730-A001-201 |
|
June 28, 2018 |
February 13, 2019 |
February 13, 2019 |
July 27, 2018 |
May 2, 2019 |
|
- Clinical Trials, Inc. and Arkansas Epilepsy Program
Little Rock, Arkansas, United States - Consultants in Epilepsy & Neurology, PLLC
Boise, Idaho, United States - Johns Hopkins University- School of Medicine
Baltimore, Maryland, United States - (and 2 more...)
|
|
| 70 |
NCT01258595 |
Completed
Has Results |
A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age |
|
- Biological: High-Dose Trivalent Inactivated Influenza Vaccine
- Biological: Trivalent Inactivated Influenza Vaccine
|
Interventional
|
Phase 2 |
- Sanofi Pasteur, a Sanofi Company
- Sanofi
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Geometric Mean Titers (GMTs) of Vaccine Antibodies Before and After Vaccination With Either Fluzone® High-Dose or Fluzone® Vaccine.
- Geometric Mean of Individual Titer Ratios (GMTRs) of Vaccine Antibodies Before and After Vaccination With Either Fluzone® High-Dose or Fluzone® Vaccine
- Percentage of Participants With Seroconversion After Vaccination With Either Fluzone® High-Dose or Fluzone® Vaccine
- (and 2 more...)
|
300 |
All |
50 Years to 64 Years (Adult) |
NCT01258595 |
FIM09
UTN: U1111-1113-3648 |
|
November 2010 |
March 2011 |
April 2011 |
December 13, 2010 |
May 16, 2016 |
October 27, 2011 |
- Idaho Falls, Idaho, United States
- Columbia, Maryland, United States
- Ellicott City, Maryland, United States
- (and 2 more...)
|
|
| 71 |
NCT02061917 |
Completed |
Switching From Usual Brand Cigarettes to a Tobacco-heating Cigarette or Snus |
|
- Other: Tobacco-Heating Cigarette
- Other: Snus (Smokeless Tobacco)
- Other: Tobacco-Burning Cigarette
|
Interventional
|
Not Applicable |
- R.J. Reynolds Tobacco Company
- Analytisch-biologisches Forschungslabor GmbH
- Arista Laboratories
- (and 4 more...)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Urinary Tobacco Exposure Biomarkers from Weeks 0 to 12
- Change in Blood Tobacco Exposure Biomarkers from Weeks 0 to 12
- Change in Markers of Exposure and Potential Harm from Weeks 0 to 12
- (and 15 more...)
|
163 |
All |
28 Years to 55 Years (Adult) |
NCT02061917 |
HSD-0702 |
QoL |
February 2007 |
November 2007 |
November 2009 |
February 13, 2014 |
February 17, 2016 |
|
- Covance Clinical Research Unit, Inc.
Daytona, Florida, United States - Covance Clinical Research Unit, Inc.
Boise, Idaho, United States - Covance Clinical Research Unit, Inc.
Portland, Oregon, United States - (and 2 more...)
|
|
| 72 |
NCT03994796 |
Recruiting |
Genetic Testing in Guiding Treatment for Patients With Brain Metastases |
- CDK Gene Mutation
- Metastatic Malignant Neoplasm in the Brain
- Metastatic Malignant Solid Neoplasm
- (and 3 more...)
|
- Drug: Abemaciclib
- Drug: PI3K Inhibitor GDC-0084
- Drug: Entrectinib
|
Interventional
|
Phase 2 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Genentech, Inc.
|
Other / NIH / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate in the brain
- Systemic response for extracranial disease
- Clinical benefit rate for central nervous system (CNS)
- (and 8 more...)
|
150 |
All |
18 Years and older (Adult, Older Adult) |
NCT03994796 |
A071701
NCI-2019-00744
U10CA180821 |
|
August 15, 2019 |
July 2021 |
June 2025 |
June 21, 2019 |
September 13, 2019 |
|
- Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, United States - Saint Alphonsus Cancer Care Center-Caldwell
Caldwell, Idaho, United States - Kootenai Medical Center
Coeur d'Alene, Idaho, United States - (and 83 more...)
|
|
| 73 |
NCT03448367 |
Recruiting |
FreeStyle Libre Flash Glucose Monitoring System Post Approval Study for Pediatric Patients |
|
- Device: FreeStyle Libre Flash Glucose Monitoring System
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Safety of the FreeStyle Libre Flash Glucose Monitoring System
|
400 |
All |
4 Years to 17 Years (Child) |
NCT03448367 |
ADC-US-PMS-17168-002 |
|
February 27, 2018 |
February 2021 |
February 2021 |
February 28, 2018 |
June 18, 2019 |
|
- Sansum Diabetes Research Institute
Santa Barbara, California, United States - Barbara Davis Center for Diabetes
Aurora, Colorado, United States - Rocky Mountain Diabetes & Osteoporosis Center
Idaho Falls, Idaho, United States - (and 2 more...)
|
|
| 74 |
NCT00351533 |
Completed
Has Results |
A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI) |
- Respiratory Distress Syndrome, Adult
- Acute Lung Injury
- Acute Respiratory Distress Syndrome
|
- Drug: Fish oil (eicosapentaenoic acid and docosahexanoic acid)
|
Interventional
|
Phase 2 |
- University of Washington
- National Heart, Lung, and Blood Institute (NHLBI)
- American Thoracic Society
- (and 2 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Bronchoalveolar Lavage Fluid (BALF) Interleukin (IL)-8
- Change in BALF Leukotriene B4
- Change in BALF Interleukin-6
- (and 15 more...)
|
90 |
All |
18 Years and older (Adult, Older Adult) |
NCT00351533 |
28503-A
05-7895-A 03 |
|
July 2006 |
January 2009 |
August 2009 |
July 13, 2006 |
October 3, 2011 |
October 3, 2011 |
- St. Alphonsus Medical Center
Boise, Idaho, United States - Oregon Health Sciences University
Portland, Oregon, United States - University of Vermont/Fletcher Allen Health Care
Burlington, Vermont, United States - (and 2 more...)
|
|
| 75 |
NCT04095364 |
Recruiting |
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian or Primary Peritoneal Cancer |
- Low Grade Ovarian Serous Adenocarcinoma
- Primary Peritoneal Low Grade Serous Adenocarcinoma
- Stage II Ovarian Cancer AJCC v8
- (and 12 more...)
|
- Drug: Carboplatin
- Drug: Letrozole
- Drug: Paclitaxel
|
Interventional
|
Phase 3 |
- NRG Oncology
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival (PFS)
- Incidence of adverse events (AE)
- Objective response rate (ORR)
- (and 3 more...)
|
450 |
Female |
18 Years and older (Adult, Older Adult) |
NCT04095364 |
NRG-GY019
NCI-2019-01460
U10CA180868 |
|
August 26, 2019 |
February 1, 2027 |
February 1, 2028 |
September 19, 2019 |
September 19, 2019 |
|
- Augusta University Medical Center
Augusta, Georgia, United States - Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, United States - Saint Alphonsus Cancer Care Center-Caldwell
Caldwell, Idaho, United States - (and 51 more...)
|
|
| 76 |
NCT03607448 |
Completed |
Freestyle Libre Flash Glucose Monitoring System |
|
- Device: Freestyle Libre Flash Glucose Monitoring System
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- System Performance
- System Related Adverse Device Effects
|
153 |
All |
18 Years and older (Adult, Older Adult) |
NCT03607448 |
ADC-US-VAL-18174 |
|
July 23, 2018 |
November 21, 2018 |
November 21, 2018 |
July 31, 2018 |
November 29, 2018 |
|
- AMCR
Escondido, California, United States - Sansum Diabetes Research Institute
Santa Barbara, California, United States - Diablo Clinical Research
Walnut Creek, California, United States - (and 2 more...)
|
|
| 77 |
NCT02078674 |
Completed |
A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant |
|
- Biological: Monovalent Avian Influenza VLP (H7N9)
- Biological: Matrix-M1™ adjuvant
- Biological: Placebo
|
Interventional
|
Phase 1
Phase 2 |
- Novavax
- Department of Health and Human Services
|
Industry / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Assessment of Safety
- Immunogenicity as assessed by hemagglutination-inhibiting (HAI) antibody titers against the vaccine-homologous A/Anhui/1/13 (H7N9) virus.
- Immunogenicity as assessed by neuraminidase-inhibiting antibodies to N9.
|
610 |
All |
18 Years to 64 Years (Adult) |
NCT02078674 |
FLU-MI7A-201 |
|
March 2014 |
July 2015 |
July 2015 |
March 5, 2014 |
September 23, 2016 |
|
- Diablo Clinical Research
Walnut Creek, California, United States - Miami Research Associates
Miami, Florida, United States - Advanced Clinical Research
Meridian, Idaho, United States - (and 2 more...)
|
|
| 78 |
NCT01877395 |
Completed |
Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen |
|
- Biological: Purified Vero Rabies Vaccine (VRVg)
- Biological: Imovax® Rabies: inactivated rabies vaccine
|
Interventional
|
Phase 2 |
- Sanofi Pasteur, a Sanofi Company
- Sanofi
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- Number of participants with rabies virus neutralizing antibody (RVNA) titer ≥ 0.5 IU/mL at Day 42 (14 days after the last vaccination of primary vaccination series).
- Number of Participants Reporting Solicited Injection Site Reactions, Solicited Systemic Reactions, Unsolicited Systemic Reactions, and Serious Adverse Events Occurring Throughout the Trial
- Geometric mean titer ratio (GMTR) following vaccination with either Purified Vero Rabies Vaccine, Serum Free or Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post exposure Regimen
|
342 |
All |
18 Years to 64 Years (Adult) |
NCT01877395 |
VRV04
U1111-1117-7447 |
|
June 2013 |
May 2014 |
September 2014 |
June 13, 2013 |
December 3, 2014 |
|
- Pembroke Pines, Florida, United States
- South Miami, Florida, United States
- Boise, Idaho, United States
- (and 2 more...)
|
|
| 79 |
NCT00442169 |
Completed
Has Results |
Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults |
|
- Biological: ChimeriVax-WN02 Low Dose
- Biological: ChimeriVax-WN02 Medium Dose
- Biological: ChimeriVax-WN02 High Dose
- (and 2 more...)
|
Interventional
|
Phase 2 |
- Sanofi Pasteur, a Sanofi Company
- Sanofi
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Number of Participants With Fourfold or Greater Post-vaccination Titers (Seroconversion).
- Number of Viremic Participants Post-vaccination
- Treatment-emergent Adverse Events Reported As Related to Study Treatment in at Least 5% of Participants in Any Active Treatment Group Post-vaccination.
- Geometric Mean Titers of Neutralizing Antibody Titers Pre- and Post-vaccination.
|
208 |
All |
18 Years and older (Adult, Older Adult) |
NCT00442169 |
H-244-003 |
|
December 2005 |
June 2008 |
April 2009 |
March 1, 2007 |
April 14, 2016 |
February 14, 2011 |
- HOPE Research Institute
Phoenix, Arizona, United States - Idaho Infectious Diseases, PLLC
Idaho Falls, Idaho, United States - PRA International Clinical Pharmacology Center
Lenexa, Kansas, United States - (and 2 more...)
|
|
| 80 |
NCT01288586 |
Completed |
Post-Approval Study to Investigate the Long Term (8 Year) Survivorship of STAR Ankle Among Continued Access Study Patients |
|
- Device: Scandinavian Total Ankle Replacement System (STAR Ankle)
|
Observational
|
|
|
Industry |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- The primary objective for this study is to examine the long-term survivorship of the STAR Ankle
- American Orthopaedic Foot and Ankle Society questionnaire will be used to evaluate and monitor the progress of patients following foot and ankle surgery.
|
87 |
All |
18 Years and older (Adult, Older Adult) |
NCT01288586 |
STAR 8 Year |
STAR 8 |
October 5, 2009 |
November 14, 2016 |
November 14, 2016 |
February 2, 2011 |
March 27, 2017 |
|
- Oakland Bone & Joint Specialists
Oakland, California, United States - Foundations of Orthopedic Research and Education
Temple Terrace, Florida, United States - St. Alphonsus Medical Group, Coughlin Foot & Ankle Clinic
Boise, Idaho, United States - (and 2 more...)
|
|
| 81 |
NCT00299520 |
Completed |
Phase 3 Safety and Efficacy Study of I.V. Iclaprim v Linezolid in cSSSI (ASSIST-1) |
- Complicated Skin and Skin Structure Infection
|
- Drug: intravenous iclaprim or intravenous linezolid
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Clinical cure rate (the ratio of number of clinically cured patients to the total number of patients in the population) at 7 to 14 days after the end of therapy
- Microbiological eradication rate at 7-14 days after end of therapy.
- Safety evaluations conducted during the study
|
|
All |
18 Years and older (Adult, Older Adult) |
NCT00299520 |
Protocol No. ICLA-08-CSI1
ASSIST-1 |
|
June 2005 |
|
July 2006 |
March 7, 2006 |
April 4, 2008 |
|
- e-Study Site
National City, California, United States - VA Medical Center
Boise, Idaho, United States - Infectious Disease of Indiana
Indianapolis, Indiana, United States - (and 2 more...)
|
|
| 82 |
NCT01516216 |
Active, not recruiting |
Study of Vitamin D in Untreated Metastatic Colorectal Cancer |
- Metastatic Colorectal Cancer
|
- Drug: FOLFOX + bevacizumab
- Dietary Supplement: Vitamin D
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Progression Free Survival
- Overall Survival
- Objective tumor response rate
- (and 5 more...)
|
120 |
All |
18 Years and older (Adult, Older Adult) |
NCT01516216 |
11-436 |
|
March 2012 |
November 2019 |
June 2020 |
January 24, 2012 |
February 12, 2019 |
|
- Mountain States Tumor Institute at St. Luke's Regional Medical Center
Boise, Idaho, United States - Mountain States Tumor Institute- Fruitland
Fruitland, Idaho, United States - Mountain States Tumor Institute - Meridian
Meridian, Idaho, United States - (and 15 more...)
|
|
| 83 |
NCT03914612 |
Recruiting |
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer |
- Endometrial Clear Cell Adenocarcinoma
- Endometrial Endometrioid Adenocarcinoma
- Endometrial Mixed Cell Adenocarcinoma
- (and 18 more...)
|
- Drug: Carboplatin
- Drug: Paclitaxel
- Biological: Pembrolizumab
- (and 3 more...)
|
Interventional
|
Phase 3 |
- National Cancer Institute (NCI)
- NRG Oncology
|
NIH / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Progression-free survival (PFS)
- Incidence of adverse events
- Objective tumor response
- (and 7 more...)
|
810 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03914612 |
NCI-2019-02186
NRG-GY018
U10CA180868 |
|
July 16, 2019 |
June 30, 2023 |
June 30, 2023 |
April 15, 2019 |
October 15, 2019 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Alaska Women's Cancer Care
Anchorage, Alaska, United States - Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
Savannah, Georgia, United States - (and 27 more...)
|
|
| 84 |
NCT04032093 |
Recruiting |
A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN |
- Respiratory Tract Infection
|
- Biological: RSV vaccine
- Biological: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Percentage of participants reporting local reactions and systemic events from day of vaccination (Day 1) until Day 7
- Percentage of participants reporting Adverse Events (AE) within 1 month after vaccination
- Percentage of participants reporting obstetric complications, medically attended adverse events (MAE) and serious adverse events (SAE) throughout the study
- (and 7 more...)
|
650 |
Female |
18 Years to 49 Years (Adult) |
NCT04032093 |
C3671003 |
|
August 7, 2019 |
February 25, 2021 |
February 25, 2021 |
July 25, 2019 |
August 22, 2019 |
|
- Internal Medicine & Pediatrics of Cullman, P.C.
Cullman, Alabama, United States - MedPharmics, LLC
Phoenix, Arizona, United States - Mesquite Pediatrics
Tucson, Arizona, United States - (and 85 more...)
|
|
| 85 |
NCT03971474 |
Recruiting |
Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) |
- Recurrent Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8
|
- Drug: Docetaxel
- Drug: Gemcitabine
- Drug: Gemcitabine Hydrochloride
- (and 4 more...)
|
Interventional
|
Phase 2 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Investigator assessed-progression-free survival (IA-PFS)
- Duration of response (DOR)
- (and 2 more...)
|
144 |
All |
18 Years and older (Adult, Older Adult) |
NCT03971474 |
S1800A
NCI-2019-00703
U10CA180888 |
|
May 17, 2019 |
February 1, 2023 |
February 1, 2023 |
June 3, 2019 |
August 8, 2019 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 594 more...)
|
|
| 86 |
NCT03944941 |
Recruiting |
Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer |
- Skin Squamous Cell Carcinoma
- Metastatic Skin Cancer
|
- Drug: Avelumab
- Drug: Cetuximab
|
Interventional
|
Phase 2 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Prolonging of progression free survival (PFS) on avelumab and cetuximab compared to avelumab alone
- Confirmed objective response rate (RR)
- Clinical benefit rate (CBR)
- (and 3 more...)
|
59 |
All |
18 Years and older (Adult, Older Adult) |
NCT03944941 |
A091802
NCI-2018-02652
U10CA180821 |
|
May 17, 2019 |
December 2022 |
December 2023 |
May 10, 2019 |
September 19, 2019 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 224 more...)
|
|
| 87 |
NCT03937635 |
Recruiting |
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma |
- Smoldering Plasma Cell Myeloma
|
- Biological: Daratumumab
- Drug: Dexamethasone
- Drug: Lenalidomide
- (and 2 more...)
|
Interventional
|
Phase 3 |
- ECOG-ACRIN Cancer Research Group
- National Cancer Institute (NCI)
- Eastern Cooperative Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Functional Assessment of Cancer Therapy-General (FACT-G) score
- Progression-free survival (PFS)
- (and 9 more...)
|
288 |
All |
18 Years and older (Adult, Older Adult) |
NCT03937635 |
EAA173
NCI-2018-02611
U10CA180820 |
|
April 30, 2019 |
November 30, 2023 |
November 30, 2028 |
May 6, 2019 |
October 7, 2019 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 318 more...)
|
|
| 88 |
NCT03907488 |
Recruiting |
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma |
- Ann Arbor Stage III Hodgkin Lymphoma
- Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma
- Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma
- (and 11 more...)
|
- Drug: Brentuximab Vedotin
- Drug: Dacarbazine
- Drug: Doxorubicin
- (and 9 more...)
|
Interventional
|
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival (PFS)
- Overall survival
- Event-free survival (EFS)
- (and 2 more...)
|
987 |
All |
12 Years and older (Child, Adult, Older Adult) |
NCT03907488 |
NCI-2019-01960
S1826
U10CA180888 |
|
July 19, 2019 |
March 1, 2024 |
March 1, 2024 |
April 9, 2019 |
October 18, 2019 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - Alaska Oncology and Hematology LLC
Anchorage, Alaska, United States - (and 254 more...)
|
|
| 89 |
NCT03866382 |
Recruiting |
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors |
- Bladder Adenocarcinoma
- Bladder Mixed Adenocarcinoma
- Bladder Small Cell Carcinoma
- (and 36 more...)
|
- Drug: Cabozantinib
- Drug: Cabozantinib S-malate
- Biological: Ipilimumab
- Biological: Nivolumab
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate (ORR)
- Duration of response
- Progression-free survival (PFS)
- (and 3 more...)
|
186 |
All |
18 Years and older (Adult, Older Adult) |
NCT03866382 |
NCI-2019-01266
A031702
U10CA180821 |
|
April 12, 2019 |
February 28, 2023 |
February 28, 2023 |
March 7, 2019 |
October 18, 2019 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 431 more...)
|
|
| 90 |
NCT03851445 |
Recruiting |
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer |
- Previously Treated Non-Small Cell Lung Cancer
|
|
Interventional
|
Phase 2
Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Screening Success (Tissue Submission)
- Screening Success (Adequate Tissue)
- Screening Success (Prescreening-to-sub-study Assignment)
- (and 3 more...)
|
5000 |
All |
18 Years and older (Adult, Older Adult) |
NCT03851445 |
LUNGMAP
NCI-2018-01540 |
|
January 28, 2019 |
January 28, 2024 |
January 28, 2024 |
February 22, 2019 |
September 9, 2019 |
|
- University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Alaska Oncology and Hematology LLC
Anchorage, Alaska, United States - Anchorage Oncology Centre
Anchorage, Alaska, United States - (and 644 more...)
|
|
| 91 |
NCT03845296 |
Recruiting |
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) |
- Deleterious BRCA1 Gene Mutation
- Deleterious BRCA2 Gene Mutation
- Loss of Heterozygosity
- (and 8 more...)
|
|
Interventional
|
Phase 2 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Investigator assessed progression free survival (PFS)
- Duration of response (DoR)
- Overall survival
- (and 2 more...)
|
80 |
All |
Child, Adult, Older Adult |
NCT03845296 |
S1900A
NCI-2018-02129
U10CA180888 |
|
January 28, 2019 |
July 1, 2021 |
July 1, 2021 |
February 19, 2019 |
September 9, 2019 |
|
- University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 806 more...)
|
|
| 92 |
NCT03811015 |
Recruiting |
Testing Maintenance Immunotherapy Versus Observation in Patients With Oropharynx Cancer |
- Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
|
- Drug: Cisplatin
- Radiation: Intensity-Modulated Radiation Therapy
- Biological: Nivolumab
- Other: Patient Observation
|
Interventional
|
Phase 2
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival (PFS) (Phase II)
- Overall survival (OS) (Phase III)
- Negative (standardized qualitative) 12 week post therapy (cisplatin + radiation therapy [RT]) FDG positron emission tomography/computed tomography (PET/CT) associated with OS for patients who have a PET/CT
- (and 8 more...)
|
744 |
All |
18 Years and older (Adult, Older Adult) |
NCT03811015 |
NCI-2019-00179
EA3161
U10CA180820 |
|
June 20, 2019 |
January 1, 2027 |
January 1, 2027 |
January 21, 2019 |
October 15, 2019 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 328 more...)
|
|
| 93 |
NCT03887702 |
Recruiting |
Tenofovir Alafenamide in Preventing Liver Complications in Participants With Current or Past Hepatitis B Virus Who Are Receiving Anti-Cancer Therapy for Solid Tumors |
- Hepatitis B Virus Positive
- Malignant Solid Neoplasm
|
- Other: Best Practice
- Other: Laboratory Biomarker Analysis
- Drug: Tenofovir Alafenamide
|
Interventional
|
Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- Time until adverse liver outcome, assessed by incidence of adverse liver outcome graded according to Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4.0
- Incidence of hepatitis B Virus (HBV) reactivation among patients with solid malignancies and chronic or past HBV infection during or after completion of anti-cancer therapy
- HBV reactivation rate
- (and 4 more...)
|
444 |
All |
18 Years and older (Adult, Older Adult) |
NCT03887702 |
S1614
NCI-2018-00592
SWOG-S1614
UG1CA189974 |
|
February 21, 2019 |
February 21, 2025 |
February 21, 2025 |
March 25, 2019 |
September 9, 2019 |
|
- Mercy Hospital Fort Smith
Fort Smith, Arkansas, United States - Tibor Rubin VA Medical Center
Long Beach, California, United States - Broward Health Medical Center
Fort Lauderdale, Florida, United States - (and 120 more...)
|
|
| 94 |
NCT03793179 |
Recruiting |
Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer |
- Lung Non-Squamous Non-Small Cell Carcinoma
- Stage IIIB Lung Cancer AJCC v8
- Stage IIIC Lung Cancer AJCC v8
- Stage IVA Lung Cancer AJCC v8
|
- Drug: Carboplatin
- Biological: Pembrolizumab
- Drug: Pemetrexed
|
Interventional
|
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Progression-free survival (PFS)
- Best objective response
- (and 2 more...)
|
846 |
All |
18 Years and older (Adult, Older Adult) |
NCT03793179 |
NCI-2018-03695
EA5163
U10CA180820 |
|
February 28, 2019 |
September 30, 2021 |
September 30, 2021 |
January 4, 2019 |
October 18, 2019 |
|
- University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 741 more...)
|
|
| 95 |
NCT03793166 |
Recruiting |
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study |
- Clear Cell Renal Cell Carcinoma
- Metastatic Malignant Neoplasm in Lymph Node
- Metastatic Malignant Neoplasm in the Bone
- (and 4 more...)
|
- Drug: Cabozantinib
- Biological: Ipilimumab
- Biological: Nivolumab
- (and 2 more...)
|
Interventional
|
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Progression-free survival (PFS)
- Complete response (CR) (randomized patients)
- (and 3 more...)
|
1046 |
All |
18 Years and older (Adult, Older Adult) |
NCT03793166 |
NCI-2018-03694
A031704
U10CA180821 |
|
May 9, 2019 |
September 15, 2021 |
September 15, 2021 |
January 4, 2019 |
October 15, 2019 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 532 more...)
|
|
| 96 |
NCT03768414 |
Recruiting |
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers |
- Stage III Distal Bile Duct Cancer AJCC v8
- Stage III Gallbladder Cancer AJCC v8
- Stage III Intrahepatic Cholangiocarcinoma AJCC v8
- (and 14 more...)
|
- Drug: Cisplatin
- Drug: Gemcitabine Hydrochloride
- Drug: Nab-paclitaxel
|
Interventional
|
Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Incidence of adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
- Progression-free survival (PFS)
- (and 3 more...)
|
268 |
All |
18 Years and older (Adult, Older Adult) |
NCT03768414 |
S1815
NCI-2018-01920
U10CA180888 |
|
December 3, 2018 |
January 1, 2024 |
January 1, 2024 |
December 7, 2018 |
September 9, 2019 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 579 more...)
|
|
| 97 |
NCT03839940 |
Recruiting |
Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer |
|
- Drug: Dexamethasone
- Other: Placebo
- Other: Questionnaire
- (and 2 more...)
|
Interventional
|
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Incidence rate of the mTOR inhibitor-associated stomatitis (mIAS)-related pain based on daily self-reports via the numerical analogue scale
- Severity of mouth pain scores
- Incidence of grade > 2 mIAS as measured by the SWISH trial
- (and 14 more...)
|
279 |
All |
18 Years and older (Adult, Older Adult) |
NCT03839940 |
A221701
NCI-2018-02648
UG1CA189823 |
|
February 15, 2019 |
February 1, 2020 |
September 2022 |
February 15, 2019 |
September 19, 2019 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Kingman Regional Medical Center
Kingman, Arizona, United States - Mercy Hospital Fort Smith
Fort Smith, Arkansas, United States - (and 298 more...)
|
|
| 98 |
NCT03737981 |
Recruiting |
Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia |
- Chronic Lymphocytic Leukemia
|
- Drug: Ibrutinib
- Biological: Obinutuzumab
- Other: Observation
- Drug: Venetoclax
|
Interventional
|
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival (PFS)
- Bone marrow (BM) minimal residual disease (MRD)- complete response (CR) rate
- Overall survival (OS)
- Incidence of adverse events
|
454 |
All |
70 Years and older (Older Adult) |
NCT03737981 |
NCI-2018-02485
A041702
U10CA180821 |
|
January 4, 2019 |
June 1, 2027 |
June 1, 2027 |
November 12, 2018 |
October 18, 2019 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 689 more...)
|
|
| 99 |
NCT03723928 |
Recruiting |
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer |
- Anatomic Stage IV Breast Cancer AJCC v8
- Estrogen Receptor Positive
- HER2/Neu Negative
- (and 3 more...)
|
- Other: Usual care disease monitoring
- Other: Serum Tumor Marker directed disease monitoring
- Other: Quality-of-Life Assessment
- Other: Anxiety Questionnaire Administration
|
Interventional
|
Not Applicable |
- Southwest Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Assessment of whether patients monitored with STMDDM have non-inferior overall survival compared with patients monitored with usual care
- Cumulative direct healthcare costs of patients monitored with STMDDM versus usual care
- Assessment of anxiety of patients monitored with STMDDM compared to patients monitored with usual care
- Assessment of quality of life of patients monitored with STMDDM versus patients monitored with usual care
|
1320 |
All |
18 Years and older (Adult, Older Adult) |
NCT03723928 |
S1703
NCI-2018-00090
SWOG-S1703
UG1CA189974 |
|
July 16, 2018 |
July 15, 2027 |
July 15, 2027 |
October 30, 2018 |
August 8, 2019 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 492 more...)
|
|
| 100 |
NCT00644293 |
Completed |
A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin Sustained Release Versus 3-Day Azithromycin for the Treatment of Strep Throat in Adolescents and Adults |
|
- Drug: azithromycin (Zithromax)
- Drug: placebo
- Drug: azithromycin SR
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- bacteriologic response in the Bacteriologic per Protocol population
- sponsor assessment of clinical response in the Bacteriologic per Protocol population
- bacteriologic response for the remaining study populations
- (and 4 more...)
|
598 |
All |
13 Years and older (Child, Adult, Older Adult) |
NCT00644293 |
A0661119 |
|
January 2003 |
|
April 2004 |
March 26, 2008 |
June 8, 2011 |
|
- Pfizer Investigational Site
Clearwater, Florida, United States - Pfizer Investigational Site
Boise, Idaho, United States - Pfizer Investigational Site
Boise, Idaho, United States - (and 56 more...)
|
|
Create an RSS feed from your search for:
Download the search results for: